News

ELVN-001, an experimental treatment for chronic myeloid leukemia (CML), a type of blood cancer, is showing promising proof-of-concept effects for killing cancer cells in patients…

Adding the experimental therapy elraglusib to standard chemotherapy led to statistically significant improvements in survival for people with metastatic pancreatic ductal adenocarcinoma (PDAC), a form…

Optieum Biotechnologies and Genezen are teaming up to help develop OPTF01, an experimental cell therapy for glioblastoma, an aggressive form of glioma.

The use of testosterone as part of gender-affirming care does not increase the risk of gynecological cancers in transgender men or gender-diverse people, a study…

The U.S. Food and Drug Administration (FDA) has granted fast track status to ISB 2001, an experimental therapy for difficult-to-treat multiple myeloma. The designation…

Oral therapy revumenib showed positive results in patients with relapsed or refractory acute myeloid leukemia (AML) driven by NPM1 mutations, with nearly half of participants…

Theriva Biologics’ experimental treatment VCN-01 safely increased survival when used in addition to chemotherapy for people with newly diagnosed metastatic pancreatic ductal adenocarcinoma (PDAC),…

Contract development and manufacturing organization Viralgen said it has scaled up production of Trogenix’s glioblastoma treatment TGX-007, as the companies move the gene therapy…

Thursday is World Ovarian Cancer Day, an annual effort to raise awareness about ovarian cancer, the second most common type of gynecological cancer.

The European Commission (EC) has conditionally approved Regeneron Pharmaceuticals’ linvoseltamab, now Lynozyfic, to treat adults with relapsed or refractory multiple myeloma (RRMM).